Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)

Novo Nordisk Q2 results: obesity drug growth (Wegovy pill) offsets pricing pressure. Shares fell 6%, but DCF suggests 25% ...

Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals

Chief Executive Mike Doustdar's comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent ...

Novo Nordisk's Q2 profit beats forecasts, raises outlook

COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk, the maker of weight-loss drug Wegovy, reported a second-quarter adjusted operating profit above forecasts on Tuesday and raised its full-year profit and ...

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.

Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial

Novo Nordisk shares plunged on Friday, erasing more than $30 billion in market value after the Danish drugmaker said a ...

Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case

Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie from a district court in ...

Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
FIRSTonline

Novo Nordisk's financials are solid, but the market is rejecting them: the stock price slides, amid concerns about pipeline risks.

Novo Nordisk loses ground in Copenhagen after a decline on Wall Street. The increase in 2026 estimates isn't enough to dispel ...